Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Montri Chamnanphon,1 Khunthong Pechatanan,2 Ekapob Sirachainan,3 Narumol Trachu,4 Wasun Chantratita,5 Ekawat Pasomsub,5 Wilai Noonpakdee,6 Insee Sensorn,1,7 Chonlaphat Sukasem11Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital,...

Full description

Bibliographic Details
Main Authors:	Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-05-01
Series:	Pharmacogenomics and Personalized Medicine
Online Access:	http://www.dovepress.com/association-of-cyp2d6-and-cyp2c19-polymorphisms-and-disease-free-survi-a13151

Similar Items

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
by: Sirachainan E, et al.
Published: (2012-10-01)

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2013-08-01)

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2016-04-01)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
by: Charoenchokthavee W, et al.
Published: (2016-08-01)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
by: Charoenchokthavee W, et al.
Published: (2017-04-01)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
by: Sukasem C, et al.
Published: (2013-08-01)

CYP2D6 polymorphisms and their influence on risperidone treatment
by: Puangpetch A, et al.
Published: (2016-12-01)

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
by: Chamnanphon M, et al.
Published: (2020-11-01)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
by: Guigao Lin, et al.
Published: (2016-01-01)

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
by: Areepium N, et al.
Published: (2013-08-01)

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
by: Per Damkier, et al.
Published: (2017-08-01)

Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population
by: Rattanaporn Sukprasong, et al.
Published: (2021-06-01)

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
by: Lu J, et al.
Published: (2017-11-01)

Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
by: PLOS ONE Staff
Published: (2016-01-01)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
by: Sumonrat Chuwongwattana, et al.
Published: (2020-12-01)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
by: Clara Inkyung Lee, et al.
Published: (2020-12-01)

Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine
by: Chamnanphon M, et al.
Published: (2020-01-01)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
by: Jennifer D. Brooks, et al.
Published: (2018-12-01)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
by: A. B. Sanchez-Spitman, et al.
Published: (2021-01-01)

Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions
by: Boštjan Šeruga, et al.
Published: (2012-08-01)

The Impact of Combination Tamoxifen and CYP2D6 Inhibitory Antidepressants on The Treatment of Breast Cancer
by: Yi-Ching Wang, et al.
Published: (2013)

Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
by: Yaowaluck Hongkaew, et al.
Published: (2021-02-01)

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
by: Danny W K Lum, et al.
Published: (2013-01-01)

The Effects of H2S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
by: Xianqin Wang, et al.
Published: (2013-12-01)

Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
by: Kristin eDickschen, et al.
Published: (2012-05-01)

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
by: Damronglerd P, et al.
Published: (2015-10-01)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
by: Mirza Bojić, et al.
Published: (2019-09-01)

Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population
by: Trachu N, et al.
Published: (2017-10-01)

Characterisation of <it>CYP2C8</it>, <it>CYP2C9 </it>and <it>CYP2C19 </it>polymorphisms in a Ghanaian population
by: Dodoo Alexander NO, et al.
Published: (2009-12-01)

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
by: Tessa A. M. Mulder, et al.
Published: (2021-02-01)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)

Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
by: Sara S. Reis, et al.
Published: (2019-07-01)

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J, et al.

The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J., et al.

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
by: Maria eJohansson, et al.
Published: (2014-03-01)

Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
by: Ana Fernández-Santander, et al.
Published: (2013-01-01)

Maternal protein restriction during lactation modulated the expression and activity of rat offspring hepatic CYP1A1, CYP1A2, CYP2B1, CYP2B2, and CYP2E1 during development
by: N. Meireles Da Costa, et al.

The effect of lycopene on the total cytochrome P450, CYP1A2 and CYP2E1
by: Melva Louisa, et al.
Published: (2009-12-01)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
by: Ingrid F. Metzger, et al.
Published: (2019-11-01)